Taylor & Francis Group
Browse
imor_a_1751402_sm1391.pdf (145.1 kB)

Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial

Download (145.1 kB)
journal contribution
posted on 2020-04-23, 14:41 authored by Masataka Kuwana, Takashi Ogura, Shigeki Makino, Sakae Homma, Yasuhiro Kondoh, Aiko Saito, Hiroyuki Ugai, Martina Gahlemann, Kazuhiko Takehara, Arata Azuma

We examined the efficacy and safety of nintedanib in Japanese patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the global Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial.

Randomised patients received oral nintedanib 150 mg (N = 34) twice daily or placebo (N = 36) until the last patient reached 52 weeks of treatment (up to 100 weeks). Data were analysed using a subgroup analysis model with Japanese and non-Japanese patients as subgroup variables.

In Japanese patients, the adjusted annual rate of forced vital capacity (FVC) decline over 52 weeks was –86.2 mL/year (nintedanib) and –90.9 mL/year (placebo); treatment difference, 4.67 mL/year (95% confidence interval, −103.28, 112.63). Treatment effect heterogeneity between Japanese and non-Japanese patients was not detected (treatment-by-visit-by-subgroup interaction; p = .49). FVC decline was smaller for nintedanib versus placebo through 100 weeks in Japanese patients. The most commonly reported adverse events with nintedanib were gastrointestinal and liver disorder events; most were mild-to-moderate in severity.

In both Japanese and non-Japanese patients with SSc-ILD, nintedanib slowed the progression of ILD, with no heterogeneity detected between the subgroups. The safety profile for nintedanib in Japanese patients was similar to that observed in patients with idiopathic pulmonary fibrosis (ClinicalTrials.gov: NCT02597933).

Funding

This study was sponsored by Boehringer Ingelheim, manufacturer of nintedanib. Medical writing assistance was provided by Serina Stretton, PhD, CMPP and Rebecca Lew, PhD, CMPP of ProScribe – Envision Pharma Group, and was funded by Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP3).

History

Usage metrics

    Modern Rheumatology

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC